5nance5nance
5nance5nance
HomeScreens
LOGINGET FREE ACCOUNT

Strides Pharma Science Ltd.

•
strides.comBSE: 532531NSE: STAR
Market Cap₹ 11,045 Cr.
Current Price
High / Low₹ 1,231 / 769
Stock P/E45.4
Book Value₹ 364
Price to Book2.63
Dividend Yield0.42 %
ROCE7.2 %
ROE5.7 %
Face Value₹ 10

Add ratio to table

ABOUT

KEY POINTS

Revenue Breakup Mar 2024 • Pharmaceutical business: 100.0%

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence
50%
View full sector analysis →

PROS

  • Promoters have been increasing their shareholding - up 2.1pp over 2 years
  • Latest quarter profit grew 446.3% YoY, showing strong momentum
  • Strong cash generation - operating cash flow backs reported profits (CFO/PAT 3.14x)
  • Company generates healthy free cash flow
  • Attractively priced for its growth - PEG of 0.2
  • Institutional investors have been accumulating - FII+DII up 2.5pp

CONS

  • A large part of profit comes from other income (101.4% of PBT)
  • Company has a low return on equity of 2.2% over last 3 years
  • Company has a low return on capital employed of 4.8%
  • Company has delivered a poor sales growth of 3.3% over past five years
  • Recurring exceptional / one-off items are inflating headline profit

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs
Part ofNIFTY MICROCAP250NIFTY TOTAL MKT
S.No.Name
1.SUNPHARMA1868.5037.06448315.740.862901.2326.5315299.8810.9819.1128.81
2.DIVISLAB9482.7586.06251737.220.32902.0065.503080.0027.8021.5140.75
3.TORNTPHARM4931.9086.01187593.620.77566.003.284921.0057.3219.2733.81
4.ZYDUSLIFE1129.0024.95112618.180.09990.20-34.908017.0023.9721.3924.54
5.CIPLA1368.0032.79110515.040.95785.55-39.187119.284.1316.0016.73
6.LAURUSLABS1933.2595.54104455.860.10362.07123.942026.3129.1018.2031.50
7.AUROPHARMA1690.0026.1997238.860.241032.0325.229150.3517.4412.7620.54
8.LUPIN2092.0017.3095660.020.861416.9816.018276.8934.2828.8629.59
9.DRREDDY1143.2029.6195420.610.70435.60-69.108099.80-5.2113.7510.63
10.MANKIND2266.0045.8293596.020.04574.0929.124030.5912.8913.2426.30
11.GLENMARK2439.5538.2968850.120.10482.83927.884018.4831.3520.3520.03
12.STAR1198.2518.0011044.600.42165.4956.731265.4113.0118.5718.06
Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
475553380603513520551556499522554606583
420514378492448464477488431460472531576
Operating Profit5638111165557468676281747
OPM %11.69%6.96%0.39%18.48%12.68%10.66%13.45%12.22%13.48%11.92%14.67%12.28%1.18%
1219-0268242122141034-75
Interest37423639414234293029272729
Depreciation21232222212121222222222526
Profit before Tax9-7-57761216212816251352785
Tax %12.38%1.46%-6.35%-3.72%9.75%-5.37%30.12%43.08%18.66%-26.19%9.58%38.33%13.96%
Net Profit8-7-60791117151613321221673
0.89-0.75-6.598.581.181.881.621.751.453.4813.221.777.91

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
1,3821,4701,5371,6921,8581,9791,8541,8662,1392,1802,264
1,2111,2731,3981,4871,6981,9021,7721,7241,8881,9782,039
Operating Profit1711971392041597783142251202225
OPM %12.35%13.41%9.04%12.08%8.57%3.87%4.46%7.60%11.75%9.27%9.92%
1541271119311712385625720646
Interest728254676574139139146114112
Depreciation70788394991049487859195
Profit before Tax18316411313611222-65-2378203271
Tax %16.81%4.68%-1.22%11.85%29.91%-737.77%107.23%-5.85%24.24%9.58%10.41%
Net Profit152156114120781805-2459184243
EPS12.1299.6112.3213.438.7220.070.52-2.646.4219.92—
Dividend Payout %26.49%11.44%23.48%104.25%28.66%0.00%289.31%-94.64%62.32%25.10%—

COMPOUNDED SALES GROWTH

10 Years:
0%
5 Years:
3%
3 Years:
6%

COMPOUNDED PROFIT GROWTH

10 Years:
3%
5 Years:
19%
3 Years:
240%

STOCK PRICE CAGR

10 Years:
—
5 Years:
—
3 Years:
—
1 Year:
39%

RETURN ON EQUITY

10 Years:
3%
5 Years:
2%
3 Years:
2%
Last Year:
6%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Corporate actions

2026

Jul 31

₹ 0.50

Rs.5.0000 per share(50%)Final Dividend

2025

Jul 22

₹ 0.40

Rs.4.0000 per share(40%)Final Dividend

2024

Sep 9

₹ 0.25

Rs.2.5000 per share(25%)Final Dividend

2023

Aug 4

₹ 0.15

Rs.1.5000 per share(15%)Final Dividend

2021

Aug 5

₹ 0.25

Rs.2.5000 per share(25%)Final Dividend

2018

Sep 12

₹ 0.20

Rs.2.0000 per share(20%)Final Dividend

2017

Sep 7

₹ 0.45

Rs.4.5000 per share(45%)Dividend

2016

Jul 21

₹ 0.40

Rs.4.0000 per share(40%)Dividend

2026

Jul 21

₹ 0.50

Rs.5.0000 per share(50%)Final Dividend

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital89909090909090929292
3,1343,0633,1603,0633,1543,3143,3453,4333,1003,191
1,6576098138959071,2721,3991,5771,1091,134
Trade Payables471391509490735644643544485686
1107811382613646138145179
Total Liabilities5,4624,2324,5834,5765,1465,3565,5255,7834,9315,282
1,124498497578577604584736756785
Capital Work in Progress100877389813016716684
2,5201,7772,1492,1712,3952,4002,4922,3641,8481,868
410270473463689513491498432580
00000001,5651,4531,521
Cash & Bank95801811107314861153041
1,2141,5211,2101,1651,3311,7941,856434346402
Total Assets5,4624,2324,5834,5765,1465,3565,5255,7834,9315,282

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
4498377170116-304142-14421278
Cash from Investing-344447-16663-27619-183-70-138-69
Cash from Financing-67-707123-204-492511193-370-199
0-194-3-3-42-137010-8610

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026

Shareholding Pattern

Numbers in percentages

Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
25.8625.8426.8228.3028.3027.8627.8627.9127.91
26.7130.0828.4828.3228.0228.5129.5228.6828.40
18.1718.2416.9213.7213.3012.9813.0214.4415.42
0.010.010.010.010.010.010.010.010.01
28.8725.8327.7729.6530.3730.6429.5928.9528.28

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-08-19
Press Release

2026-08-19 - Strides Pharma Science Limited has informed the Exchange regarding a press release dated August 19, 2026, titled "Strides receives USFDA Establishment Inspection Report (EIR) for flagship facility in Bengaluru".

2026-08-18
Shareholders meeting

2026-08-18 - Strides Pharma Science Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on August 14, 2026. Further, the company has informed the Exchange regarding voting results.

2026-08-14
Shareholders meeting

2026-08-14 - Strides Pharma Science Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on August 14, 2026

2026-08-03
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-03 - Strides Pharma Science Limited has informed the Exchange about Transcript of Earnings Call pertaining to Unaudited Financial Results of the Company for the quarter ended June 30, 2026.

2026-08-01
Copy of Newspaper Publication

2026-08-01 - Strides Pharma Science Limited has informed the Exchange about Copy of Newspaper Publication- Unaudited Financial Results for the quarter ended June 30, 2026

2026-07-31
Analysts/Institutional Investor Meet/Con. Call Updates

2026-07-31 - Strides Pharma Science Limited has informed the Exchange about the link for Earnings Call pertaining to unaudited financial results for Q1 FY27

2026-07-31
General Updates

2026-07-31 - Strides Pharma Science Limited has informed the Exchange about Investor Presentation for Earnings call on Q1 FY 2027

2026-07-31
Press Release

2026-07-31 - Strides Pharma Science Limited has informed the Exchange regarding a press release dated July 31, 2026, titled "Strides Delivers Steady Performance with Q1FY27; Revenue at ₹12,654m, Grew 13% YoY; Ex-US Markets Grew 17% YoY".

2026-07-31
Outcome of Board Meeting

2026-07-31 - Strides Pharma Science Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.

News

Recent coverage and analyst commentary for STAR

Loading news…

🤖

AI Stock Analyst

Strides Pharma Science Ltd.

🔒

Sign in to Chat with AI

Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.

✨ Sign In to Chat

Free 5nance Account

5nance5nance

Stock analysis and screening tool

5nanceAI © 2020-2026

Made with ❤️ in India.

Data provided by Accord Fintech

Terms & Privacy.

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nance5nance

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nanceAI © 2020-2026

Data provided by Accord Fintech

Made with ❤️ in India.

HomeScreens
Login